EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Targeting Neuroinflammation in Alzheimer's Disease: Repurposed Nucleoside Reverse Transcriptase Inhibitors and the Therapeutic Potential of Kamuvudine‐9

Mariyam Hussain, Mohammad Ikram, Divya Vohora

Fundamental & Clinical Pharmacology · 2026-05 · 40 (3)

DOI: 10.1111/fcp.70079 ↗

At a glance

Übersichtsarbeit in Fundamental & Clinical Pharmacology, published online on 2026-03-26. Written by Mariyam Hussain and 2 co-authors. Institution: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Major MEDLINE topics: Alzheimer Disease, Reverse Transcriptase Inhibitors, Neuroinflammatory Diseases. 100 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Alzheimer's disease (AD) is a progressive neurological illness that causes cognitive deterioration. Current medications only help with the symptoms to a limited extent. Over the past decade, nucleoside reverse transcriptase inhibitors (NRTIs), historically used as antiretrovirals, have appeared as surprising contenders for modifying AD . Aside from their antiviral activity, NRTIs have immunomodulatory actions, such as inhibiting the NLRP3 inflammasome, lowering amyloid and tau pathology and modulating neuroinflammation. A second‐generation analogue, Kamuvudine‐9, has been designed to balance these neuroprotective advantages with reduced mitochondrial toxicity and off‐target antiviral effects, offering a safer long‐term solution for chronic neurodegenerative disorders. This review synthesises mechanistic data, preclinical data, observational studies and new clinical findings to make a unified case for NRTIs and K‐9 as multitarget therapeutic compounds in AD . By emphasising their dual mechanism, retroelement inhibition and inflammasome blockade coupled with innovation in drug delivery and pharmacogenomics, we highlight how repurposing this class would remake the therapeutic landscape. In contrast to amyloid‐directed interventions, NRTIs and K‐9 act on converging inflammatory and genetic mechanisms that mediate both amyloid and tau pathology, making them universal modulators of disease course. Prospects for future advances in precision medicine, nanocarrier delivery and large‐scale validation of interventions may reveal a new generation of accessible, disease‐modifying treatments for AD .

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseaseReverse Transcriptase InhibitorsNeuroinflammatory DiseasesHumansAnimalsDrug RepositioningNeuroprotective AgentsInflammasomes

Author keywords

Alzheimer's diseaseKamuvudine‐9NLRP3 inflammasomeamyloid‐beta pathologydrug repurposingneuroinflammation

Substances

Reverse Transcriptase InhibitorsNeuroprotective AgentsInflammasomes

Authors and institutions

  • Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
  • Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.

Cite

APA

Hussain, M., Ikram, M., & Vohora, D. (2026). Targeting Neuroinflammation in Alzheimer's Disease: Repurposed Nucleoside Reverse Transcriptase Inhibitors and the Therapeutic Potential of Kamuvudine‐9. Fundamental & Clinical Pharmacology, 40(3). https://doi.org/10.1111/fcp.70079

Vancouver

Hussain M, Ikram M, Vohora D. Targeting Neuroinflammation in Alzheimer's Disease: Repurposed Nucleoside Reverse Transcriptase Inhibitors and the Therapeutic Potential of Kamuvudine‐9. Fundamental & Clinical Pharmacology. 2026;40(3). doi:10.1111/fcp.70079

BibTeX
@article{Hussain2026,
  author = {Hussain, Mariyam and Ikram, Mohammad and Vohora, Divya},
  title = {Targeting Neuroinflammation in Alzheimer's Disease: Repurposed Nucleoside Reverse Transcriptase Inhibitors and the Therapeutic Potential of Kamuvudine‐9},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2026},
  volume = {40},
  number = {3},
  doi = {10.1111/fcp.70079}
}
Start for free →